Company Overview - Bristol Myers Squibb is one of the world's largest pharmaceutical companies, known for its long and successful track record in a highly competitive sector with high drug development costs [2] - The company is currently focusing on cardiovascular, cancer, and immune-related medicines, which are significant healthcare opportunities, despite the market's current fascination with GLP-1 weight-loss drugs [4] Financial Performance - The stock is approximately 25% below its late 2022 highs, presenting a potential recovery opportunity alongside a dividend yield of 4%, which is above the average pharmaceutical stock yield of 1.7% [5] - The payout ratio for dividends is around 70%, indicating a sustainable dividend policy, as the company has a history of regularly increasing dividends and maintaining them during tough times [5] - Key financial metrics include a market cap of $127 billion, a gross margin of 65.89%, and a current stock price of $62.37, with a day's range of $61.18 to $62.67 [6][7] Patent and Product Pipeline - Bristol Myers Squibb's Opdivo cancer drug is set to lose patent protection in 2028, raising investor concerns; however, the company is exploring alternative delivery methods to potentially extend patent protections [7] - The company has a pipeline of other drugs in development, demonstrating its ability to manage patent expirations, which are a normal aspect of the pharmaceutical business [8] Investment Opportunity - The current market conditions present an opportunity to invest in an out-of-favor stock with a relatively high yield, allowing for potential growth through dividend reinvestment [9] - While Bristol Myers Squibb should not be the sole investment, it can serve as a strong foundation for a diversified portfolio, enabling investors to take on more risk in other areas [9]

Group 1 - The article promotes a subscription service called "The Dividend Dogcatcher" which provides insights and portfolios for dividend stocks [1] - It highlights a live video segment called "Underdog Daily Dividend Show" that features potential investment candidates [1] - The article encourages audience engagement by inviting comments on favorite or least favorite stock tickers for future reports [1]

Energy Transfer (NYSE: ET) is a toll taker, operating one of the largest midstream businesses in North America. And it has been very rewarding for income investors of late. That comes from both the distribution yield, which is a lofty 7%, and distribution growth. Here's what you need to know before you buy it. Energy Transfer has a good streak going Energy Transfer's distribution was increased every quarter in 2025. Every quarter in 2024. Every quarter in 2023. And every quarter in 2022. That's the kind ...

IBM just got hit with one of its worst single-day drops in years. Shares fell over 13.2% on Feb. 23, 2026, closing at $223.35. The culprit? Anthropicannounced its Claude Code tool could automate much of the tedious, expensive work involved in COBOL modernization — a key IBM (IBM) business. That panic-driven sell-off pushed IBM stock down more than 24% year to date. For growth investors, that's a problem. But for dividend hunters, the drop may have opened a door worth walking through. The question isn't w ...

Pfizer (NYSE: PFE) is one of the world's largest and most respected pharmaceutical companies. That is an important backdrop for dividend investors to consider as they look at the stock's lofty 6.4% dividend yield. For reference, the average pharma stock has a yield of just 1.7%. There's a reason to buy Pfizer beyond the yield. Pfizer gets you most of the way to 10% If you buy Pfizer and collect that 6.4% dividend yield, you are roughly two-thirds of the way toward the 10% return that most investors expec ...

Core Viewpoint - AbbVie is a large pharmaceutical company with a diverse product portfolio, and its attractive dividend yield of 2.9% makes it appealing to dividend investors [1][2]. Dividend Yield Comparison - AbbVie's dividend yield of 2.9% is significantly higher than the S&P 500's yield of 1.1% and the average pharmaceutical company's yield of 1.7%, providing investors with 1.8 percentage points more than the broader market and 1.2 percentage points more than the average drug stock [2]. Dividend Sustainability - AbbVie has a history of reliable dividend growth, with a 200% increase over the past decade, indicating a strong commitment to rewarding investors [4]. - The payout ratio exceeds 100%, but when considering the cash dividend payout ratio, which is around 60%, the sustainability of the dividend appears more favorable [5]. Business Stability - AbbVie's esthetics business, particularly Botox, offers a stable cash flow foundation despite the loss of patent protection, suggesting resilience against typical patent cycle impacts faced by other drugmakers [6]. Investment Potential - AbbVie presents an opportunity for healthcare diversification in dividend portfolios, with an attractive yield and potential for a growing dividend stream, making it a solid choice for long-term, income-focused investors [7].

Pharmaceutical giant Pfizer (NYSE: PFE) recently had to drop its internally developed GLP-1 weight loss drug candidate. The unfortunate outcome is that the company has had to watch rivals Novo Nordisk and Eli Lilly build early leads in this fast-growing drug niche. With Pfizer facing patent expirations ahead -- and now this GLP-1 setback -- Wall Street remains downbeat on the stock. But that's a potential opportunity for long-term investors. Where to invest $1,000 right now? Our analyst team just reveale ...

Core Viewpoint - Conagra Brands offers a substantial 7% dividend yield, attracting dividend investors, but faces significant risks that may affect its attractiveness as an investment [3][5][6] Investment Considerations Buy Conagra Brands? - The primary reason to consider buying Conagra is its high dividend yield of 7%, appealing to dividend-focused investors [3] - As a consumer staples company, Conagra is viewed as a safe investment during market volatility, providing essential products at reasonable prices [3] Sell Conagra Brands? - The dividend payout ratio is concerning, especially since the company reported a loss, with the ratio previously exceeding 100%, indicating potential risks to the dividend's safety [5][6] - In the fiscal second quarter of 2026, Conagra reported a loss of $1.39 per share, primarily due to non-cash goodwill and brand impairment charges, which, if excluded, would have resulted in earnings of $0.45 per share, covering the $0.35 quarterly dividend [6] Hold Conagra Brands? - Investors who have benefited from the stock's price increase in 2026 may consider taking profits and reallocating to higher-quality competitors like Coca-Cola, despite the potential loss of yield [9] - Conagra's organic sales declined by 3% in the fiscal second quarter of 2026, contrasting with Coca-Cola's 5% increase, highlighting challenges in maintaining sales amid changing consumer preferences [10]

Core Viewpoint - Energy Transfer offers a high dividend yield of nearly 7.2%, significantly higher than the S&P 500's yield of 1.2%, making it an attractive investment for income generation [1][4]. Dividend and Investment Requirements - Energy Transfer pays quarterly distributions of $0.335 per unit, totaling $1.34 annually, with a 3% increase in distribution over the past year [4][6]. - To generate $500 monthly, an investment of approximately $84,000 is required at the current price of $18.75 per unit, needing 4,478 units to achieve an annual income of $6,000 [4][5]. Comparison with Other Investments - In contrast, generating the same $500 monthly income from an S&P 500 index fund would require an investment of nearly $522,000, highlighting the efficiency of Energy Transfer's higher yield [5]. Financial Stability and Growth - Energy Transfer maintains a stable cash flow, with 90% derived from predictable fee-based sources, and pays out only about 50% of its cash flow in dividends, allowing for reinvestment in expansion projects [6]. - The company plans to spend over $5 billion on growth capital this year, with projects expected to enter commercial service through the end of the decade, supporting annual distribution increases of 3% to 5% [7]. Investment Considerations - Despite its attractive yield, Energy Transfer was not included in a recent list of the 10 best stocks for investors by The Motley Fool Stock Advisor, suggesting a need for careful consideration before investing [8].

Core Insights - The Schwab US Dividend Equity ETF (SCHD) is currently the most popular dividend ETF in the market, but there are alternative options that may offer higher growth potential, particularly in a strong technology sector [1] - The Vanguard Dividend Appreciation ETF (VIG) is highlighted as one of the alternative options alongside SCHD [1] Summary by Category - **Popular Dividend ETFs** - SCHD is recognized as the leading dividend ETF in popularity [1] - **Alternative Options** - Other dividend ETFs are suggested for consideration, especially during periods of strong technology performance [1] - VIG is specifically mentioned as a notable alternative to SCHD [1]